Equities

TheraCryf PLC

TCF:LSE

TheraCryf PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.21
  • Today's Change0.00 / 0.00%
  • Shares traded604.75k
  • 1 Year change-80.00%
  • Beta2.6777
Data delayed at least 20 minutes, as of Feb 06 2026 14:29 GMT.
More ▼

Profile data is unavailable for this security.

About the company

TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-2.01m
  • Incorporated2014
  • Employees9.00
  • Location
    TheraCryf PLCSuite 24G13 - Block 24 Alderley ParkCongleton Road, Nether AlderleyNETHERTON SK10 4TGUnited KingdomGBR
  • Phone+44 16 2531 5090
  • Websitehttps://theracryf.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Roquefort Therapeutics PLC0.00-882.45k1.96m1.001.96m1.00
ValiRx Plc49.78k-1.78m2.56m14.002.56m14.00
N4 Pharma PLC7.07k-1.07m3.95m4.003.95m4.00
TheraCryf PLC0.00-2.01m4.51m9.004.51m9.00
Cizzle Biotechnology Holdings PLC0.00-1.12m6.14m67.006.14m67.00
Futura Medical PLC7.93m-6.29m7.41m12.007.41m12.00
OptiBiotix Health PLC1.15m-191.00k7.90m5.007.90m5.00
IXICO PLC6.53m-1.65m9.50m79.009.50m79.00
Genflow Biosciences PLC0.00-1.80m10.86m5.0010.86m5.00
Solvonis Therapeutics PLC0.00-2.60m16.34m--16.34m--
Fusion Antibodies PLC1.60m-1.47m19.07m24.0019.07m24.00
Data as of Feb 06 2026. Currency figures normalised to TheraCryf PLC's reporting currency: UK Pound GBX

Institutional shareholders

43.94%Per cent of shares held by top holders
HolderShares% Held
Fiske Plc (Broker)as of 01 Dec 2025430.07m20.01%
First Equity Ltd.as of 29 May 2025179.00m8.33%
IG Markets Ltd.as of 01 Dec 202591.29m4.25%
Oberon Investments Ltd. (GB Investment Management)as of 29 May 202580.48m3.75%
KW Investment Management Ltd.as of 01 Dec 202540.38m1.88%
Hargreaves Lansdown Fund Managers Ltd.as of 01 Dec 202533.26m1.55%
Rathbones Investment Management Ltd.as of 11 Mar 202524.83m1.16%
Rowan Dartington & Co. Ltd. (Broker)as of 01 Dec 202522.45m1.05%
Octopus Investments Ltd.as of 11 Mar 202521.88m1.02%
Vulpes Investment Management Pte Ltd.as of 11 Apr 202420.55m0.96%
More ▼
Data from 31 Mar 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.